TEVA vs. KVUE
TEVA (Teva Pharmaceutical Industries Limited) and KVUE (Kenvue Inc.) are both stocks. TEVA operates in Drug Manufacturers - Specialty & Generic (Healthcare), while KVUE operates in Household & Personal Products (Consumer Defensive). Over the past 3 years, TEVA returned 61.02%/yr vs -7.96%/yr for KVUE. At a 0.10 correlation, their price movements are largely independent.
Performance
TEVA vs. KVUE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TEVA achieves a 0.87% return, which is significantly lower than KVUE's 7.52% return.
TEVA
- 1D
- -3.32%
- 1M
- -7.60%
- YTD
- 0.87%
- 6M
- 3.83%
- 1Y
- 84.53%
- 3Y*
- 61.02%
- 5Y*
- 25.48%
- 10Y*
- -4.49%
KVUE
- 1D
- 0.61%
- 1M
- 5.66%
- YTD
- 7.52%
- 6M
- 8.47%
- 1Y
- -11.23%
- 3Y*
- -7.96%
- 5Y*
- —
- 10Y*
- —
TEVA vs. KVUE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
TEVA Teva Pharmaceutical Industries Limited | 0.87% | 41.61% | 111.11% | 18.64% |
KVUE Kenvue Inc. | 7.52% | -15.86% | 3.12% | -14.06% |
Correlation
The correlation between TEVA and KVUE is 0.09, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.09 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (All Time) Calculated using the full available price history since May 4, 2023 | 0.10 |
Fundamentals
TEVA:
$37.11B
KVUE:
$34.83B
TEVA:
$1.34
KVUE:
$0.84
TEVA:
23.53
KVUE:
21.48
TEVA:
2.12
KVUE:
2.28
TEVA:
4.51
KVUE:
3.28
TEVA:
$17.35B
KVUE:
$15.29B
TEVA:
$9.03B
KVUE:
$8.93B
TEVA:
$3.05B
KVUE:
$3.03B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TEVA vs. KVUE — Risk / Return Rank
TEVA
KVUE
TEVA vs. KVUE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and Kenvue Inc. (KVUE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TEVA | KVUE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +2.54 | ||
| Sortino ratioReturn per unit of downside risk | +3.66 | ||
| Omega ratioGain probability vs. loss probability | 1.42 | 0.96 | +0.47 |
| Calmar ratioReturn relative to maximum drawdown | 3.90 | -0.30 | +4.20 |
| Martin ratioReturn relative to average drawdown | 11.35 | -0.55 | +11.90 |
Loading charts...
Drawdowns
TEVA vs. KVUE - Drawdown Comparison
The maximum TEVA drawdown since its inception was -90.89%, which is greater than KVUE's maximum drawdown of -44.08%. Use the drawdown chart below to compare losses from any high point for TEVA and KVUE.
Loading charts...
Drawdown Indicators
| TEVA | KVUE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -90.89% | -44.08% | -46.81% |
Max Drawdown (1Y)Largest decline over 1 year | -21.79% | -37.63% | +15.84% |
Max Drawdown (3Y)Largest decline over 3 years | -43.70% | -42.08% | -1.62% |
Max Drawdown (5Y)Largest decline over 5 years | -43.70% | — | — |
Max Drawdown (10Y)Largest decline over 10 years | -88.41% | — | — |
Current DrawdownCurrent decline from peak | -53.47% | -25.56% | -27.91% |
Average DrawdownAverage peak-to-trough decline | -32.01% | -21.04% | -10.97% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.47% | 20.52% | -13.05% |
Volatility
TEVA vs. KVUE - Volatility Comparison
Teva Pharmaceutical Industries Limited (TEVA) has a higher volatility of 10.98% compared to Kenvue Inc. (KVUE) at 7.28%. This indicates that TEVA's price experiences larger fluctuations and is considered to be riskier than KVUE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TEVA | KVUE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 10.98% | 7.28% | +3.70% |
Volatility (6M)Calculated over the trailing 6-month period | 24.19% | 14.46% | +9.73% |
Volatility (1Y)Calculated over the trailing 1-year period | 38.87% | 32.28% | +6.59% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 42.85% | 28.76% | +14.09% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 47.37% | 28.76% | +18.61% |
Dividends
TEVA vs. KVUE - Dividend Comparison
TEVA has not paid dividends to shareholders, while KVUE's dividend yield for the trailing twelve months is around 4.58%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
KVUE Kenvue Inc. | 4.58% | 4.78% | 3.79% | 1.86% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
TEVA Teva Pharmaceutical Industries Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3.88% | 3.19% | 1.77% |
Financials
TEVA vs. KVUE - Financials Comparison
This section allows you to compare key financial metrics between Teva Pharmaceutical Industries Limited and Kenvue Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TEVA vs. KVUE - Profitability Comparison
TEVA - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a gross profit of 1.97B and revenue of 3.98B. Therefore, the gross margin over that period was 49.5%.
KVUE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kenvue Inc. reported a gross profit of 2.30B and revenue of 3.91B. Therefore, the gross margin over that period was 58.9%.
TEVA - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported an operating income of 652.00M and revenue of 3.98B, resulting in an operating margin of 16.4%.
KVUE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kenvue Inc. reported an operating income of 767.00M and revenue of 3.91B, resulting in an operating margin of 19.6%.
TEVA - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Teva Pharmaceutical Industries Limited reported a net income of 369.00M and revenue of 3.98B, resulting in a net margin of 9.3%.
KVUE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kenvue Inc. reported a net income of 474.00M and revenue of 3.91B, resulting in a net margin of 12.1%.
Frequently Asked Questions
TEVA and KVUE have a correlation of 0.09, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TEVA has higher volatility (10.98%) compared to KVUE (7.28%). In terms of maximum drawdown, TEVA dropped -90.89% vs KVUE's -44.08%.
TEVA currently has the higher Sharpe Ratio (2.19 vs -0.35), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TEVA and KVUE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer